1. Pink Sheet

Part D Catastrophic Coverage: Manufacturers Could Agree To Increased ‘Liability’

 
• By Cathy Kelly

But drug makers want their financial contribution to go toward reducing beneficiary costs, not to replace plans’ insurance risk, according to comments submitted to two House committees on draft legislation.

Hands of an old man counting expenses on medicine and fees .Count the pennies. - Image
House Draft Bill Would Cap Medicare Part D Drug Costs

Prescription drug makers are amenable to shouldering some costs in the catastrophic phase of the Medicare Part D benefit to help create a spending cap for beneficiaries, according to industry comments on draft legislation being developed by the House Way and Means and Energy and Commerce committees.

The draft bill, released by the committees on 24 May, would set a cap on beneficiary cost sharing at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Indegene Exec On DTP Distribution As A ‘Tactical Solution’, Feasibility Of MFN Model

 
• By Anju Ghangurde

Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US, including potentially introducing new intermediaries into the system. Questions on MFN's feasibility and why it may be “catastrophic” to biopharma were also part of the discussion

Best Laid Plans: A Chronology Of Post-Pandemic COVID-19 Vaccines

 
• By Bridget Silverman

Quick responses to late-breaking changes to US FDA COVID-19 vaccine policy kept Novavax's Nuvaxovid and Moderna's mNexspike close to expected approval timelines despite revised indications and new post-marketing trial commitments.

Last Minute Course Shifts, Focus On Unknowns: What Sponsors Should Learn From Prasad’s Interventions

 
• By Sarah Karlin-Smith

The once and current CBER director’s justification for his COVID-19 decision stands as a warning of the uncertainty sponsors, particularly those in the vaccine space, may now face at FDA.